Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural heart disease monitoring and critical care. Valued at $48 billion by market capitalization, the company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceutical products. The world’s leading structural heart innovation company is expected to announce its fiscal first quarter earnings for 2026 in the near term.
Ahead of the event, analysts expect EW to post earnings of $0.72 per share on a diluted basis, up 12.5% ​​from $0.64 per share in the year-ago quarter. The company surpassed consensus estimates in three of the last four quarters and missed estimates on another occasion.
For the full year, analysts expect EW to post EPS of $2.96, up 15.6% from $2.56 in fiscal 2025. Its EPS is expected to rise 11.5% year-over-year to $3.30 in fiscal 2027.
EW stock has outpaced the S&P 500 Index ($SPX)’s gains of 13.4% over the past 52 weeks, with the stock up 15.5% during this period. Similarly, it outperformed the marginal returns of the State Street Health Care Select Sector ETF SPDR (XLV) over the same time period.
EW continues to outperform, driven by strong TAVR momentum and the success of its SAPIEN valve iterations. By advancing next-generation technologies such as the SAPIEN M3 (the first transseptal mitral replacement), the company is strategically positioned to achieve its TMTT sales goal of $2 billion by 2030. These innovations highlight how established healthcare companies can accelerate growth through “blockbuster” medical devices, making earnings periods essential to gain management insights that extend beyond standard FDA approval notices.
The analyst consensus view on EW stock is moderately bullish, with an overall rating of “Moderate Buy.” Of the 30 analysts covering the stock, 18 recommend a “Strong Buy” rating, two suggest a “Moderate Buy” and 10 give a “Hold.” The average price target from EW analysts is $96.44, indicating a potential upside of 17.5% from current levels.
On the date of publication, Neha Panjwani had no (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com